Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

Summary

This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.

Timeline

Start

2023-02-24

Primary completion

2025-11-13

Completion

2025-11-13

Drugs

Indications